The bispecific antibody drugs targeting PD-L1 and VEGF simultaneously were accepted by NMPA clinical trial
On October 21, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the bispecific antibody drug (Project No.: IMM2510) independently developed by the company and simultaneously targeting PD-L1 and VEGF was accepted for NMPA clinical trial (acceptance No.: CXSL2000290). This is the third clinical trial application submitted by ImmuneOnco after the IMM01 and IMM0306 projects which are in the process of clinical trial research. It also marks the official layout of PD-1/PD-L1 target drug research in addition to the CD47 target drug research, which is another major milestone in the company's development.
IMM2510 project is a bispecific antibody drug with independent intellectual property rights, which is based on the "mAb-Trap" technology platform of ImmuneOnco. It targets the immunomodulatory target PD-L1, It blocks the binding of PD-L1 and PD-1, relieves the immune escape of tumor cells, and activates NK cells and macrophages through Fc mediated ADCC/ADCP, which plays a powerful role in tumor immunotherapy; at the same time, it inhibits tumor angiogenesis, tumor growth and tumor metastasis by targeting VEGF. Preclinical data confirmed that IMM2510 has achieved significant therapeutic effect in a variety of tumor models, and has obvious advantages in safety.
"IMM2510 project successfully submitted the ind application, which indicates that ImmuneOnco continues to develop in-depth in the field of bispecific antibody drug research. We look forward to the IMM2510 project entering into clinical trials as soon as possible." Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, said: "ImmuneOnco has been committed to the research and development of anti-tumor drugs with new immunomodulatory targets. In addition to IMM01, IMM0306 and IMM2510, several other double target specific protein drugs have also shown good development prospects. We will continue to deepen the field of anti-tumor, accelerate the pace of research and development, and develop one after another safe and efficient anti-tumor drugs, so as to bring gospel to the majority of cancer patients.
IMM2510 is an antibody receptor recombinant protein (mAb-Trap) targeting PD-L1 and VEGF at the same time. It is the world's first (First-In-Class) bispecific antibody drug with independent intellectual property rights. It can act on tumor disease targets and regulate the immune system at the same time. It can activate the immune system and inhibit the growth of tumor cells to play a strong anti-tumor effect.
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and TANKTM cell therapy. The common feature of our products is to stimulate and mobilize the immune system of patients to play an anti-tumor effect, and ultimately inhibit the continued growth of tumor cells, reverse a series of malignant symptoms caused by this, so that patients gradually return to a healthy state of the body.
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573